Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 10/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.35 |
| ▸ | PDE4A | P27815 | 7/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7786551 | 0.88 | CHEK1 (0.39) | PDE4DPDE4BPDE4APDE4CSYK | |
| SCHEMBL278977 | 0.85 | SYK (0.36) | PDE4DPDE4BPDE4APDE4CSYK | |
| SCHEMBL276886 | 0.85 | SYK (0.36) | PDE4DPDE4BPDE4APDE4CSYK | |
| SCHEMBL276159 | 0.75 | PDE4D (0.35) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL279509 | 0.75 | PDE4D (0.35) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL278931 | 0.74 | CHEK1 (0.38) | PDE4DPDE4BPDE4APDE4CSYK | |
| SCHEMBL275247 | 0.74 | CHEK1 (0.38) | PDE4DPDE4BPDE4APDE4CSYK | |
| SCHEMBL274889 | 0.72 | SYK (0.42) | PDE4DPDE4BPDE4APDE4CSYK | |
| SCHEMBL279161 | 0.72 | SYK (0.39) | PDE4DPDE4BPDE4APDE4CSYK | |
| SCHEMBL276376 | 0.72 | SYK (0.39) | PDE4DPDE4BPDE4APDE4CSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217051-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217051-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20100210674-A1 | Spiroindolinone Derivatives | HOFFMANN-LA ROCHE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210674-A1 | Spiroindolinone Derivatives | HOFFMANN-LA ROCHE INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210674-A1 | Spiroindolinone Derivatives | RCC2, PKD1, SIK2 | PDE4D 2998/4885PDE4B 3436/4885PDE4A 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.